Dusseldorf - Delayed Quote EUR

PHC Holdings Corp (2GY.DU)

5.55

0.00

(0.00%)

At close: 7:54:10 PM GMT+2

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable CG

GlobeNewswire 30 days ago

SENS

PHCCF
Epredia Receives U.S. FDA 510(K) Clearance for the E1000 Dx™ Digital Pathology Solution Designed to Improve Laboratory Workflow in Cancer Diagnostics

PORTSMOUTH, N.H. & KALAMAZOO, Mich., March 04, 2025--Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), today announced U.S. Food and Drug Administration (FDA) 510(K) clearance for its E1000 Dx Digital Pathology Solution (E1000 Dx). The E1000 Dx consists of a high-speed, automated, whole-slide imaging digital scanner with medical grade viewer and advanced image management and viewer software that creates high-resolution digital images

Business Wire 2 months ago

PHCCF
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world’s first and only One Year CGM system SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S.

GlobeNewswire 2 months ago

SENS

PHCCF
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates. Recent Highlights & Accomplishments Generated preliminary unaudited fourth quarter revenue of approximately $8.3 million, and preliminary unaudited full year 2024

GlobeNewswire 4 months ago

PHCCF

SENS
Epredia Receives Innovative Technology Designation from Vizient for SlideMate™ Laser Slide Printer

PORTSMOUTH, N.H., November 01, 2024--Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE 6523), announces its SlideMate™ Laser slide printer has received an Innovative Technology Designation for improving laboratory efficiency and sample traceability from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country. Epredia exhibited SlideMate Laser at the Vizient Innovative Technology Exchange Sept. 18

Business Wire 6 months ago

PHCCF
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor

Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system. This milestone, part of the company's previously announced collaboration with Mercy, marks the world's

PR Newswire 7 months ago

SENS

PHCCF
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM

GERMANTOWN, Md. & PARSIPPANY, N.J., September 17, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the US Food and Drug Administration (FDA) has cleared the next-generation Eversense® 365 CGM system for people with Type 1 and Type 2 diabetes ag

Business Wire 8 months ago

SENS

PHCCF

Performance Overview

Return	2GY.DU	Nikkei 225 (^N225)
YTD	-143.16%	-3.66%
1-Year	-81.41%	-0.32%
3-Year	-99.48%	+43.50%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PHC Holdings Corp (2GY.DU)

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

Epredia Receives U.S. FDA 510(K) Clearance for the E1000 Dx™ Digital Pathology Solution Designed to Improve Laboratory Workflow in Cancer Diagnostics

Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

Epredia Receives Innovative Technology Designation from Vizient for SlideMate™ Laser Slide Printer

Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor

Eversense 365 Receives FDA Clearance: The World’s First One Year CGM

Performance Overview